Sensus Healthcare’s (SRTS) “Buy” Rating Reaffirmed at Roth Capital

Share on StockTwits

Sensus Healthcare (NASDAQ:SRTS)‘s stock had its “buy” rating reiterated by equities researchers at Roth Capital in a research report issued to clients and investors on Tuesday.

SRTS has been the subject of a number of other reports. Northland Securities cut shares of Sensus Healthcare from a “market perform” rating to an “under perform” rating in a research note on Tuesday, January 29th. TheStreet upgraded shares of Sensus Healthcare from a “d” rating to a “c” rating in a research note on Thursday, February 14th. Craig Hallum started coverage on shares of Sensus Healthcare in a research note on Tuesday, December 11th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine upgraded shares of Sensus Healthcare from a “hold” rating to a “buy” rating in a research note on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $10.89.

Shares of Sensus Healthcare stock opened at $7.46 on Tuesday. Sensus Healthcare has a 1-year low of $5.00 and a 1-year high of $8.88. The firm has a market capitalization of $120.96 million, a PE ratio of -53.29 and a beta of -0.43.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, February 14th. The company reported $0.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.03. Sensus Healthcare had a negative net margin of 7.65% and a negative return on equity of 12.64%. The business had revenue of $8.08 million during the quarter, compared to analysts’ expectations of $7.33 million. Research analysts anticipate that Sensus Healthcare will post 0.03 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in Sensus Healthcare by 222.5% during the 4th quarter. Geode Capital Management LLC now owns 45,034 shares of the company’s stock valued at $333,000 after purchasing an additional 31,070 shares during the last quarter. Northern Trust Corp acquired a new position in Sensus Healthcare during the 4th quarter valued at $86,000. BlackRock Inc. raised its stake in Sensus Healthcare by 10.2% during the 4th quarter. BlackRock Inc. now owns 26,031 shares of the company’s stock valued at $192,000 after purchasing an additional 2,418 shares during the last quarter. Vanguard Group Inc raised its stake in Sensus Healthcare by 48.2% during the 3rd quarter. Vanguard Group Inc now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Sensus Healthcare by 48.2% during the 3rd quarter. Vanguard Group Inc. now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares during the last quarter. Hedge funds and other institutional investors own 12.84% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

See Also: How liquidity affects the bid-ask spread

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.